320.06
-0.28 (-0.09%)
| Penutupan Terdahulu | 320.34 |
| Buka | 320.00 |
| Jumlah Dagangan | 88,019 |
| Purata Dagangan (3B) | 217,532 |
| Modal Pasaran | 8,633,566,208 |
| Harga / Pendapatan (P/E Ke hadapan) | 34.01 |
| Harga / Jualan (P/S) | 3.50 |
| Harga / Buku (P/B) | 1.30 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2025 |
| Margin Keuntungan | -85.16% |
| Margin Operasi (TTM) | 9.72% |
| EPS Cair (TTM) | -76.53 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -83.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.50% |
| Nisbah Semasa (MRQ) | 5.99 |
| Aliran Tunai Operasi (OCF TTM) | 515.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 250.23 M |
| Pulangan Atas Aset (ROA TTM) | 1.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Bio-Rad Laboratories, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 16.14% |
| % Dimiliki oleh Institusi | 93.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Veritas Asset Management Llp | 30 Sep 2025 | 844,039 |
| Parnassus Investments, Llc | 30 Sep 2025 | 315,328 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 375.00 (Citigroup, 17.17%) | Beli |
| Median | 357.50 (11.70%) | |
| Rendah | 340.00 (Wells Fargo, 6.23%) | Pegang |
| Purata | 357.50 (11.70%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 304.61 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 30 Oct 2025 | 375.00 (17.17%) | Beli | 304.61 |
| Wells Fargo | 30 Oct 2025 | 340.00 (6.23%) | Pegang | 304.61 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 29 Oct 2025 | Pengumuman | Bio-Rad Reports Third-Quarter 2025 Financial Results |
| 16 Oct 2025 | Pengumuman | Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 |
| 29 Sep 2025 | Pengumuman | Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |